Governors Lane LP Has $2.69 Million Stock Holdings in Qiagen N.V. $QGEN

Governors Lane LP increased its position in shares of Qiagen N.V. (NYSE:QGEN) by 24.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,720 shares of the company’s stock after purchasing an additional 13,698 shares during the quarter. Governors Lane LP’s holdings in Qiagen were worth $2,687,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise grew its stake in Qiagen by 1.8% during the fourth quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock worth $747,000 after buying an additional 290 shares during the last quarter. Commerce Bank boosted its holdings in shares of Qiagen by 4.9% in the 4th quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after acquiring an additional 314 shares in the last quarter. Allworth Financial LP increased its holdings in Qiagen by 20.8% during the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after purchasing an additional 317 shares in the last quarter. Truist Financial Corp increased its holdings in Qiagen by 4.1% during the 4th quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock valued at $379,000 after purchasing an additional 331 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in Qiagen by 7.1% in the 3rd quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock valued at $256,000 after purchasing an additional 378 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on QGEN. Berenberg Bank set a $45.50 target price on Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. upped their price target on shares of Qiagen from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Citigroup reissued a “neutral” rating and set a $45.00 price objective (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $48.00 target price on shares of Qiagen in a research note on Thursday, August 6th. Finally, Kepler Capital Markets set a $38.60 target price on shares of Qiagen and gave the stock a “hold” rating in a research report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Qiagen has an average rating of “Hold” and an average target price of $43.93.

Qiagen Price Performance

Shares of QGEN stock opened at $42.37 on Wednesday. The firm has a market cap of $8.73 billion, a price-to-earnings ratio of 21.71, a PEG ratio of 4.33 and a beta of 0.63. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The stock has a 50-day moving average price of $42.05 and a 200 day moving average price of $40.25.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts expect that Qiagen N.V. will post 2.43 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.